Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-09-09 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于董事、副总裁因误操作违规减持公司股份的情况说明及致歉公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding a violation by a company director and vice president who improperly reduced his shareholding without prior disclosure, which is a personal share transaction by a company director. The text includes details of the share reduction, the apology, and the company's response. It does not contain financial statements, earnings data, or regulatory filings about the company itself, but rather focuses on insider trading activity. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and specific to this insider transaction, confirming the classification.
2021-09-09 Chinese
关于召集召开2021年第一次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2021 first extraordinary general meeting (临时股东大会) of Anhui Anke Biological Engineering (Group) Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), registration procedures, agenda items (such as the proposal to amend the company articles), and attachments like proxy forms and voting instructions. There is no financial data, earnings, or audit information. The document is clearly a meeting notice and materials related to the shareholder meeting, not the meeting results or minutes. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is under 5,000 characters but contains substantive meeting details, so it is not a mere announcement of a report (RPA). Therefore, the classification is AGM-R with high confidence.
2021-09-05 Chinese
公司章程修正案（2021年9月）
Governance Information Classification · 95% confidence The document is titled as a "Company Articles of Association Amendment" (公司章程修正案) for 安徽安科生物工程（集团）股份有限公司 dated September 2021. It details specific amendments to the company's articles of association, including provisions on share repurchases, board responsibilities, voting rights, and other governance matters. The content is focused on internal governance rules and procedures rather than financial results, audit opinions, or shareholder meeting materials. There is no indication that this is a report or announcement of a report, nor is it a certification or legal proceeding update. The document is a governance-related text outlining the company's internal rules and board structure changes. Therefore, the most appropriate classification is Governance Information (CGR). The document length (6101 characters) supports it being a substantive governance document rather than a brief announcement.
2021-09-05 Chinese
关于第七届董事会第十三次会议决议的公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions passed at the 13th meeting of the 7th Board of Directors of Anhui Anke Biotechnology (Group) Co., Ltd. It details board decisions including approval of amendments to the company's articles of association and the plan to convene an extraordinary general meeting. The document is a formal disclosure of board meeting outcomes, not a full report or financial statement. It fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-09-05 Chinese
国元证券股份有限公司关于安科生物2021年半年报持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2021年半年度持续督导跟踪报告" which translates to "2021 Semi-Annual Continuous Supervision Follow-up Report" by the sponsoring securities company for the listed company Anhui Anke Bioengineering (Group) Co., Ltd. It details the sponsor's review and supervision activities over the half-year period, including information disclosure, governance, fundraising supervision, and other compliance matters. The document length is 1934 characters, which is relatively short and focused on supervision and compliance rather than full financial statements or detailed financial analysis. It does not contain comprehensive financial data or statements typical of an Interim/Quarterly Report (IR) but rather a monitoring and compliance report by the sponsor. This type of document fits best under the category of Regulatory Filings (RNS), as it is a regulatory compliance update and supervision report rather than a full financial report or announcement of voting results, management changes, or capital updates.
2021-08-25 Chinese
关于2021年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2021 Half-Year Special Report on the Deposit and Use of Raised Funds" by Anhui Anke Biotechnology (Group) Co., Ltd. It details the management, storage, and usage of funds raised through a non-public stock issuance, including specific amounts, dates, and regulatory compliance references. The content focuses on the use and management of raised capital, including bank accounts, interest income, and project investments, consistent with a specialized report on fundraising usage. The document is 5627 characters long, which is substantive and contains detailed financial and operational data about the use of raised funds for the half-year period ending June 30, 2021. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report, nor a full annual or interim financial report, but a specialized report on fundraising usage and management.
2021-08-19 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.